Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 May 2021Website:
http://www.sentibio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 76 min agoDividend
Analysts recommendations
Institutional Ownership
SNTI Latest News
Senti Biosciences (NASDAQ: SNTI ) stock is taking off on Tuesday alongside heavy pre-market trading of the preclinical biotechnology company's shares this morning. That has more than 8.5 million shares of SNTI stock changing hands as of this writing.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences:
Senti Biosciences, Inc. (SNTI) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.86 per share a year ago.
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
What type of business is Senti Biosciences?
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
What sector is Senti Biosciences in?
Senti Biosciences is in the Healthcare sector
What industry is Senti Biosciences in?
Senti Biosciences is in the Biotechnology industry
What country is Senti Biosciences from?
Senti Biosciences is headquartered in United States
When did Senti Biosciences go public?
Senti Biosciences initial public offering (IPO) was on 26 May 2021
What is Senti Biosciences website?
https://www.sentibio.com
Is Senti Biosciences in the S&P 500?
No, Senti Biosciences is not included in the S&P 500 index
Is Senti Biosciences in the NASDAQ 100?
No, Senti Biosciences is not included in the NASDAQ 100 index
Is Senti Biosciences in the Dow Jones?
No, Senti Biosciences is not included in the Dow Jones index
When does Senti Biosciences report earnings?
The next expected earnings date for Senti Biosciences is 09 August 2024